Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
1 Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
2 Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA.
3 Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
4 Oncology Research and Development, Pfizer Inc, La Jolla, CA, USA.
5 Massachusetts General Hospital Cancer Center, Boston, MA, USA.
6 Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
7 The Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA.
8 Clinical Pharmacology Oncology, Global Product Development, Pfizer Inc, San Diego, CA, USA.
9 The Ludwig Center at Harvard, Boston, MA, USA.
10 Department of Medicine, Harvard Medical School, Boston, MA, USA.
11 Division of Solid Tumor Oncology, Department of Medicine, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA. yuh@mskcc.org.
12 Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. michor@jimmy.harvard.edu.
13 Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA. michor@jimmy.harvard.edu.
14 Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA. michor@jimmy.harvard.edu.
15 The Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA. michor@jimmy.harvard.edu.
16 The Ludwig Center at Harvard, Boston, MA, USA. michor@jimmy.harvard.edu.
17 The Broad Institute of MIT and Harvard, Cambridge, MA, USA. michor@jimmy.harvard.edu.